

Synthetic Entry into 1-Phosphono-3-azabicyclo[3.1.0]hexanes


Wouter Debrouwer,[†] Thomas S. A. Heugebaert,[†] Kristof Van Hecke,[‡] and Christian V. Stevens^{*,†}

[†]SynBioC Research Group, Department of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure links 653, B-9000 Gent, Belgium

[‡]Department of Inorganic and Physical Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281-S3, B-9000 Gent, Belgium

S Supporting Information

ABSTRACT: 3-Azabicyclo[3.1.0]hex-2-en-1-yl phosphonates were prepared in a five-step reaction route from β -ketophosphonates. The key steps in this sequence are an atom-transfer radical cyclization and an unforeseen lithium–halogen exchange with *n*-BuLi. The cyclization reaction proceeds with excellent diastereoselectivity. The resulting cyclic imines were reduced, and 3-azabicyclo[3.1.0]hexan-1-yl phosphonates were obtained.



INTRODUCTION

During our ongoing research on the use of heteroatom transfer radical cyclization (HATRC) for the design of phosphonylated heterocycles,^{1–4} an unexpected synthesis of diethyl (2-phenyl-3-azabicyclo[3.1.0]hexan-1-yl)phosphonates **1** (Figure 1) has been elaborated. Bicyclic β -aminophosphonates bearing a phosphonate moiety at the bridgehead of the bicyclic structure have only scarcely been reported in literature.^{5–8}




Figure 1. New azabicyclic phosphonates **1**.

In the class of 3-azabicyclo[3.1.0]hexane scaffolds, no bicycles phosphonylated at the bridgehead have been reported. The carboxylic acid derivatives, on the other hand, which are bioisosters, have been reported in patent literature and exhibit a wide range of therapeutic activities.⁹ Amino acid **2** is a bicyclic GABA analogue,¹⁰ while **3** functions as a NK1 antagonist, counteracting emesis in cancer patients receiving chemotherapy (Figure 2).¹¹ Coupling of the azabicyclic skeleton to larger molecules furnishes antibacterial agents **4**, antihistamines, and S1P_1 agonists.^{12–14} The synthesis of a library of diethyl (2-phenyl-3-azabicyclo[3.1.0]hexan-1-yl)phosphonates was thus pursued, in view of the interesting biological features of closely related analogues and the lack of literature information regarding this new class of compounds.

RESULTS AND DISCUSSION

Bicyclic β -aminophosphonates **1** were obtained from commercially available substrates in a six-step synthetic pathway. Ten derivatives were prepared starting from differently substituted α -haloacetophenones. These substrates were evaluated for their conversion into the corresponding β -ketophosphonates **5** by a classic Michaelis–Arbuzov reaction with triethyl phosphite.

However, these α -haloacetophenones are prone to the Perkow reaction, i.e., phosphite attack across the carbonyl function yielding enol phosphate esters via a zwitterionic intermediate. Electron-withdrawing substituents on the phenyl ring promote the Perkow reaction. In order to avoid formation of these enol phosphates, two literature procedures were applied. α -Haloacetophenones were converted into the corresponding hydrazones. This prevented phosphite attack across the carbonyl function and favored the envisaged Michaelis–Arbuzov reaction (route A).¹⁵ Consecutive hydrolysis delivered the desired β -ketophosphonates **5** in good to excellent yields, as depicted in Table 1.

For α -haloacetophenones with strong electron-withdrawing groups on the phenyl ring ($\text{R} = 4\text{'-NO}_2, 4\text{'-CN}$), formation of the hydrazones appeared to be troublesome, leading to severe degradation of the reaction products. Hence, a different procedure using the $\text{MgCl}_2/\text{Et}_3\text{N}$ system with diethyl phosphonoacetic acid was evaluated and did cleanly yield the desired electron poor β -ketophosphonates after decarboxylation (route B).¹⁶ Using two different methodologies, we synthesized 10 substituted diethyl (2-oxo-2-phenylethyl)phosphonates (Table 1). When the purity of the crude reaction product was unsatisfactory, column chromatography was performed since even small impurities caused unproportionally large amounts of side products in the following steps.

Next, diethyl (2-oxo-2-phenylethyl)phosphonates **5a–j** were reacted with allylamine under Dean–Stark conditions, yielding an enamine/imine mixture **6/7a–j** in ratios around 80/20 in favor of the enamines (Scheme 1, Table 2). Only one isomer of enamine **6a–j** was formed, whereas the imines **7a–j** were obtained in both their *E* and *Z* forms, the *E* form prevailing (for exact ratios, see Table 2). These β -enaminophosphonates **6** are versatile building blocks and various syntheses of these molecules have accordingly been reported, e.g., the addition of amines to phosphonylated alkynes^{17–19} or addition of metalated dialkyl phosphonates to nitriles.^{20–23} Furthermore,

Received: May 30, 2013

Published: August 21, 2013




Figure 2. Biologically relevant carboxyl analogues.

Table 1. Yields of β -Ketophosphonates 5a–j

entry	R	route	5 (%)
a	4'-H	A	^a
b	4'-F	A	50 ^b
c	4'-Cl	A	51 ^b
d	4'-Br	A	52 ^b
e	4'-OMe	A	95 ^b
f	4'-Me	A	90
g	4'-Ph	A	99
h	3'-OMe	A	61 ^b
i	4'-NO ₂	B	51 ^b
j	4'-CN	B	50 ^b

^aCommercially available product. ^bAfter column chromatography.

they can be converted into a myriad of acyclic and cyclic compounds, such as 1-aza-1,3-dienes,^{22,24,25} 2-pyridones,²³ and pyrazoles.²⁵ In this work, the enamine/imine mixture was α,α -dihalogenated using 2 equiv of *N*-chlorosuccinimide (NCS) furnishing the α,α -dichlorinated imines **8a–j** in satisfactory yields and with high purities. No column chromatography was needed except for the derivatives with strong electron-withdrawing groups on the phenyl ring (Table 2).

With a library of α,α -dichlorinated imines **8** in hand, a HATRC was performed in order to acquire the 1-pyrrolines **11a–j**.²⁶ Usually, copper(I) complexes mediate this free-radical ring closure, and their activity can be enhanced by adding ligands that modify solubility and redox potential.²⁷ The α,α -dihalogenated imines **8a–j** were stirred with Cu(I)Cl and *N,N,N',N',N''*-pentamethyldiethylenetriamine (PMDTA) as a ligand in CH₂Cl₂ at reflux temperature, and the reaction progress was monitored using HPLC. After all starting material **8a–j** had been consumed (ca. 5 h) and the crude reaction mixture had been subjected to column chromatography, 1-pyrrolines **11a–j** were isolated in satisfactory yields (Scheme

Table 2. Yields (%) and Conformational Ratios of Enamines/Imines 6/7a–j and α,α -Dichlorinated Imines 8a–j


entry	R	yield 6 + 7	ratio 6/7	ratio E/Z	yield of 8 (%)
a	4'-H	98	83/17	65/35	95
b	4'-F	89	71/29	53/47	99
c	4'-Cl	80	72/28	51/59	97
d	4'-Br	93	49/51	60/40	82
e	4'-OMe	91	73/27	59/41	92
f	4'-Me	72	74/26	73/27	96
g	4'-Ph	91	82/18	54/46	90
h	3'-OMe	98	84/16	59/41	99
i	4'-NO ₂	83	50/50	93/7	42 ^a
j	4'-CN	88	51/49	78/22	44 ^a

^aAfter column chromatography.


2). Application of other ligating agents such as *N,N,N',N'*-tetramethylethylenediamine (TMEDA) gave similar results.

Because of the molecular reorganization caused by the free-radical cyclization process, two stereogenic centers have been introduced into the molecule (Scheme 2, **11a–j**). However, ³¹P NMR indicated a strong diastereoselectivity. Only one major product peak was present, along with some small signals accounting for the minor enantiomeric pair and a few minor impurities. The diastereoisomeric ratios are all in the range of 90/10 and only the major pair of enantiomers could be obtained in pure form (Table 3).

In order to determine the relative stereochemistry of the 1-pyrrolines **11a–j**, several NMR techniques were applied. A 2D-NOESY experiment displayed no interaction between the phosphonate ethoxy groups and H³, possibly indicating a *trans* configuration (Figure 3). Furthermore, a heteronuclear 2D-NOESY (HOESY) experiment was performed to determine if any Overhauser effect between the phosphorus atom and H³

Scheme 1. Formation of α,α -Dichlorinated Imines 8a–j

Scheme 2. Mechanism of the HATRC

Table 3. Yields (%) after Column Chromatography and Diastereoisomeric Ratios of Crude Reaction Mixtures (Based on ^{31}P NMR)

entry	R	yield of 11 (%)	dr
a	4'-H	93 ^a	90/10
b	4'-F	59	92/8
c	4'-Cl	73	90/10
d	4'-Br	43	89/11
e	4'-OMe	45	85/15
f	4'-Me	26	95/5
g	4'-Ph	37	96/4
h	3'-OMe	60	93/7
i	4'-NO ₂	23 ^b	93/7
j	4'-CN	14 ^b	95/5

^aNo column chromatography necessary. ^bAfter first crystallization; further crystallization proved difficult, so column chromatography was used if necessary.




Figure 3. Absence of NOE (dashed arrows) and determination of $^3J_{\text{HP}}$ (plain arrow).

could be detected. However, no interaction was observed in this experiment, thereby supporting the result of the previous experiment. Finally, several ^1H -uncoupled ^{31}P NMR spectra were recorded with different intensities of decoupling irradiation in order to obtain a clean signal (for details, see the Supporting Information). These experiments proved the coupling constant $^3J_{\text{HP}}$ to be 11.2 Hz (Figure 3). Literature values for $^3J_{\text{HP}}$ in five-membered rings have been reported as $^3J_{\text{HP,trans}} = 5.4\text{--}6.0$ Hz, while $^3J_{\text{HP,cis}} = 17.2\text{--}18.0$ Hz.²⁸ The coupling constant observed in **11** lies in between these two values, rendering the NMR observations inconclusive. In the end, we were able to crystallize two derivatives (**11i**, R = 4'-NO₂ and **11j**, R = 4'-CN). Opposed to the configuration suspected from the NOE NMR experiments, single-crystal X-ray diffraction indicated that the relative stereochemistry is *cis*, with a torsion angle of $-37.2(5)^\circ$ and $-33.1(3)^\circ$ for **11i** and **11j**, respectively, between the phosphorus atom and H³ (Figure 4). As both compounds **11i** and **11j** crystallized in the centrosymmetric space group $P2_1/c$, both enantiomers are present in the crystal structures.

The origin of this diastereoselectivity most likely lies in steric hindrance caused by the phosphonate's bulky ethoxy substituents, as no other obvious inducing factors are present.





Figure 4. Asymmetric unit of the crystal structure of **11j** showing thermal ellipsoids at the 40% probability level. Both enantiomers are present in the crystal structure. Disorder of the ethoxy groups is omitted for clarity.

Formation of the five-membered ring proceeds through a radical *5-exo-trig* cyclization. In the transition state **9** the allylic methylene carbon is preferentially oriented away from the bulky phosphonate moiety (Scheme 2). In this manner, the energetically most favorable five-membered ring is formed, being the one with least steric hindrance.


With this five-membered ring in hand, the initial goal was to perform a 1,4-dehydrohalogenation reaction in order to produce phosphonylated pyrroles **13** (Scheme 3).²⁹ Several bases were evaluated. Not surprisingly, weak bases such as triethylamine or potassium carbonate did not engender the desired elimination. Bases of intermediate strength such as KO-*t*-Bu and sodium hydride also failed to do so. The use of LiHMDS yielded some pyrrole **13a**, albeit in very small amounts. In order to achieve complete conversion and to speed up the reaction, *n*-BuLi was employed. However, this resulted in the formation of an unexpected new compound instead of the envisaged pyrrole **13a**. After purification and careful NMR studies, the structure of this new compound was assigned as bicyclic product **14a** (Scheme 3).

The alkyllithium reagent performed a Li-Cl exchange with the tertiary chlorine atom to yield the most stable carbanion **15a-j** (Scheme 4, only one enantiomer shown). This lithiated anion subsequently underwent an intramolecular S_N2 reaction affording bicycle **14a-j**. Conjugation with the imine bond as well as the electron-withdrawing properties of the phosphonate moiety ensure that only the tertiary chlorine is exchanged, and the primary, more accessible one, is left untouched. This hypothesis was proven by the fact that quenching the reaction

Scheme 3. Attempted Synthesis of Phosphonylated Pyrroles 13a through E2



Scheme 4. Mechanistic Proposal for the Formation of Bicyclic Phosphonates 14a–j (Only One Enantiomer Shown)



with methanol, 5 min after the addition of *n*-BuLi, yielded the same bicyclic product **14a–j**, whereas quenching with acetic acid after the same time interval yielded a mixture of starting material **11a–j**, bicycle **14a–j**, and some monochlorinated compounds. After addition of methanol, lithiated product **15a–j** was quenched by the acidic alcohol proton, but the in situ formed lithium methoxide was basic enough to deprotonate the β -imino phosphonate and accomplish the intramolecular ring closure, a process that could not be accomplished by the less basic lithium acetate. If the primary chlorine atom had been exchanged instead, lithium methoxide would not have been able to deprotonate the resulting aliphatic methyl group. This proves that the tertiary chlorine is exchanged after the addition of *n*-BuLi.


The other diastereoisomer of **11a–j**, in which the tertiary chlorine and the chloromethyl group are in a *trans* configuration, is also converted into bicyclic product **14a–j**. In this case, the formation of the three-membered ring is possible by inversion of the stereochemistry via the aza-enolate in order to obtain the necessary configuration for the ring closure. In this manner, we have achieved the unexpected synthesis of diethyl (2-phenyl-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonates **14a–j** (Table 4).

Table 4. Yields of Cyclopropanation after Column Chromatography and Reduction

entry	R	yield of 14 (%)	reduction time (h)	yield of 1 (%)
a	4'-H	76	1	84
b	4'-F	49	2	74
c	4'-Cl	33	1	85
d	4'-Br	40 ^a		<i>b</i>
e	4'-OMe	51	16	92
f	4'-Me	54	16	63
g	4'-Ph	30	24	91
h	3'-OMe	72	24	30 ^c
i	4'-NO ₂	20	4	81 ^c
j	4'-pentanoyl	36	24	60 ^c

^aInseparable mixture. ^bReduction was not performed because of impure starting material. ^cAfter column chromatography.


In the 4'-Br derivative **11d**, however, the bromine on the phenyl ring was exchanged as well as a tertiary chlorine atom, yielding inseparable mixtures of brominated, chlorinated, and dehalogenated starting materials and cyclopropanated product. Interestingly, lithium-halogen exchange in **11c** (R = 4'-Cl) occurs only on the tertiary chlorine atom and not on the chlorine on the phenyl ring as no dehalogenated products were detected. For **11j** (R = 4'-CN), the simultaneous addition of *n*-BuLi to the nitrile could not be prevented, resulting in a mixture of starting material, cyclopropanated product with the nitrile intact and cyclopropanated product with a pentanoyl substituent **14j** (Figure 5). Therefore, all of **11j** was converted into **14j** by adding an excess of *n*-BuLi.

Figure 5. Product after addition of *n*-BuLi to **11j** with loss of the nitrile functional group.

To our surprise, further derivatization of the imine bond proved to be extremely difficult. Hydrolysis in neutral, acidic, or alkaline medium was unsuccessful as well as addition of alkyllithium or Grignard reagents. N-Alkylation using methyl iodide or trimethyloxonium tetrafluoroborate in order to activate the imine bond was not successful, and reduction with NaBH₄ or LiAlH₄ failed. However, application of equimolar amounts of NaCNBH₃ and acetic acid proved to be effective for reduction to the bicyclic pyrrolidine **1a** (Scheme 5, Table 4). Reaction progress was monitored by HPLC (Table 4). The lack of reactivity of **14a–j** may be explained by steric hindrance of the imine bond caused by the bulky ethoxy groups of the phosphonate on one side and a cyclopropane proton on the other side, blocking the antibonding π^* -orbitals. Only the smallest nucleophiles can add, given the imine bond is suitably activated, i.e., by protonation.

Through this reduction, a third stereogenic center was introduced into the molecule with high diastereoselectivity (dr

Scheme 5. Reduction of Imine 14a (Only One Enantiomer Shown)



$\geq 99/1$ for all derivatives **1a–j** based on ^{31}P NMR). This observation may again be explained by strong steric hindrance at the imine bond, which forces the hydride to add from the less hindered side of the five-membered ring. This results in a racemic mixture of diethyl (2-phenyl-3-azabicyclo[3.1.0]hexan-1-yl)phosphonates, with the phenyl ring and the phosphonate moiety in a *cis* configuration.

CONCLUSION

A library of 10 azabicyclic phosphonates with a manifold of substituents on the phenyl ring was obtained in five steps. The key steps are two ring-closure reactions of which the first, i.e., the HATRC, displays an excellent diastereoselectivity. The relative stereochemistry of these compounds was confirmed by X-ray analysis. The second ring closure is accomplished through a lithium–chlorine exchange with *n*-BuLi, allowing intramolecular cyclopropanation. The acquired cyclic β -imino phosphonates proved very unreactive toward all kinds of nucleophiles, only undergoing a diastereoselective reduction with NaCNBH₃ and acetic acid. This step furnishes diethyl (2-phenyl-3-azabicyclo[3.1.0]hexan-1-yl)phosphonates in excellent yields.

EXPERIMENTAL SECTION

Commercially available products were used as received without any purification unless otherwise noted. Column chromatography was performed in a glass column with silica gel (particle size 70–200 μm , pore diameter 60 Å) using mixtures of ethyl acetate (EtOAc) and hexanes. NMR spectra were recorded at 300 MHz (^1H), 121 MHz (^{31}P), or 75 MHz (^{13}C) in CDCl₃ unless otherwise noted. 2D-NOESY spectra were recorded using a 5 s relaxation delay and a 1.5 s mixing time. Low-resolution mass spectra were obtained with a single quadrupole mass spectrometer (ESI, 70 eV). High-resolution mass spectra were obtained with a time of flight (TOF) mass spectrometer (ESI or APCI). Melting points are uncorrected.

Synthesis of Diethyl (2-Oxo-2-phenylethyl)phosphonates 5a–h. A mixture of substituted 2-chloroacetophenone or 2-bromoacetophenone (1 equiv) and methyl hydrazinecarboxylate (1.05 equiv) was dissolved in toluene (2 mL/mmol) in a round-bottom flask equipped with a Dean–Stark apparatus and heated to reflux temperature for 5 h. Triethyl phosphite was added (1.1 equiv), and the reaction mixture was refluxed for an additional 2 h. The solvent was evaporated in vacuo before the residue was redissolved in a mixture of 20 mL of acetone and 20 mL of 2 M HCl. After 3 h of stirring, the acetone was evaporated in vacuo and the residue was brought to pH 7 with 2 M NaOH before being extracted with CH₂Cl₂ (3 \times 20 mL). The combined organic phases were dried over MgSO₄ and concentrated in vacuo. If necessary, the product was purified using column chromatography.

Synthesis of Diethyl (2-Oxo-2-phenylethyl)phosphonates 5i,j. A mixture of diethyl phosphonoacetic acid (1 equiv) was dissolved in CH₃CN (2 mL/mmol), MgCl₂ (1.2 equiv) and Et₃N (2 equiv) were added, and the reaction mixture was stirred for 2 h at room temperature. Then the suspension was cooled to 0 $^\circ\text{C}$, and the desired acid chloride was dissolved in CH₃CN (1 mL/mmol) and added dropwise to the cooled solution. The reaction was allowed to slowly warm to room temperature overnight. The solvent was removed in vacuo, and the solids were redissolved in 20 mL of CH₂Cl₂ and washed

with 20 mL of 2 M HCl. The aqueous phase was extracted with CH₂Cl₂ (3 \times 20 mL) and was dried over MgSO₄. The solvent was removed in vacuo, and the product was purified using column chromatography.

Diethyl (2-(4-Cyanophenyl)-2-oxoethyl)phosphonate 5j. A 3.00 g (18.12 mmol) sample of commercially available 4-cyanobenzoyl chloride was converted into **5j**. After column chromatography, 2.55 g was obtained (9.06 mmol, 50% yield, yellow oil). ^1H NMR (300 MHz, CDCl₃) δ : 1.30 (6H, t, $J = 7.1$ Hz), 3.64 (2H, d, $^2J_{\text{HP}} = 23.1$ Hz), 4.15 (4H, dq, $^3J_{\text{HP}} = 7.4$ Hz, $J = 7.1$ Hz), 7.79 (2H, d, $J = 8.0$ Hz), 8.13 (2H, d, $J = 8.0$ Hz). ^{13}C NMR (75 MHz, CDCl₃) δ : 16.1 (d, $^3J_{\text{CP}} = 5.8$ Hz), 38.7 (d, $^1J_{\text{CP}} = 129.2$ Hz), 62.7 (d, $^2J_{\text{CP}} = 5.8$ Hz), 116.5, 117.8, 129.4, 132.4, 139.3, 190.9 (d, $^2J_{\text{CP}} = 5.8$ Hz). ^{31}P NMR (121 MHz, CDCl₃) δ : 19.18. IR (cm⁻¹) ν_{max} : 1019 (P–O), 1051 (P–O), 1248 (P=O), 1685 (C=O), 2232 (C \equiv N), 2984. MS (ESI, pos): m/z 282.3/283.0 (M + H⁺, 100/14). HRMS: m/z calcd for C₁₃H₁₇NO₄P (M + H)⁺ 282.0890, found 282.0899. Chromatography: hexanes/EtOAc 2/3, $R_f = 0.11$.

Synthesis of Diethyl (2-(Allylamino)-2-phenylvinyl)phosphonates 6a–j and 7a–j. Diethyl (2-oxo-2-phenylethyl)phosphonates **5a–j** were dissolved in toluene (1 mL/mmol) in a round-bottom flask equipped with a Dean–Stark apparatus. Allylamine (1.5 equiv) and *p*-TsOH (0.05 equiv) were added, and the reaction mixture was heated to reflux temperature and left overnight. The reaction progress was monitored using gas chromatography. After all starting material had been consumed, the solvent was removed in vacuo and the residue was redissolved in diethyl ether and washed with aqueous NaHCO₃. The organic phase was extracted with diethyl ether (3 \times 20 mL), dried over MgSO₄, and concentrated in vacuo.

Synthesis of Diethyl (2-(Allylimino)-1,1-dichloro-2-phenylethyl)phosphonates 8a–j. Diethyl (2-(allylamino)-2-phenylvinyl)phosphonates **6a–j/7a–j** were dissolved in CH₂Cl₂ (1 mL/mmol), and *N*-chlorosuccinimide was added (2 equiv). After 4 h, the reaction mixture was poured into 2 M NaOH and extracted (3 \times 20 mL CH₂Cl₂). The combined organic layers were dried over MgSO₄ and concentrated in vacuo. If necessary, the residue was purified using column chromatography.

Diethyl (2-(allylimino)-1,1-dichloro-2-phenylethyl)phosphonate 8a. 3.08 g (10.43 mmol) of enamine/imine **6a/7a** was converted into 3.61 g of **8a** (9.91 mmol, 95% yield, yellow oil). ^1H NMR (300 MHz, CDCl₃) δ : 1.37 (6H, t, $J = 7.2$ Hz), 3.86 (2H, d, $J = 5.3$ Hz), 4.27–4.48 (4H, m), 5.10 (1H, dd, $J_{\text{HHZ}} = 10.6$ Hz, $J = 1.1$ Hz), 5.21 (1H, dd, $J_{\text{HHE}} = 17.1$ Hz, $J = 1.4$ Hz), 5.90 (1H, ddt, $J_{\text{HHE}} = 17.1$ Hz, $J_{\text{HHZ}} = 10.6$ Hz, $J = 5.3$ Hz), 7.31–7.33 (2H, m), 7.43–7.44 (3H, m). ^{13}C NMR (75 MHz, CDCl₃) δ : 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 55.9, 65.4 (d, $^2J_{\text{CP}} = 6.9$ Hz), 82.0 (d, $^1J_{\text{CP}} = 176.5$ Hz), 116.3, 128.1, 128.9, 129.3, 131.7 (d, $^3J_{\text{CP}} = 5.8$ Hz), 134.3, 166.0. ^{31}P NMR (121 MHz, CDCl₃) δ : 10.96. IR (cm⁻¹) ν_{max} : 1017 (P–O), 1054 (P–O), 1265 (P=O), 1654, 2982. MS (ESI, pos): m/z 364.0/365.0/366.0 (M + H⁺, 100/16/64). HRMS: m/z calcd for C₁₅H₂₁Cl₂NO₃P (M + H)⁺ 364.0631, found 364.0642.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-fluorophenyl)ethyl)phosphonate 8b. 2.42 g (7.72 mmol) of enamine/imine **6b/7b** was converted into 2.92 g of **8b** (7.64 mmol, 99% yield, yellow oil). ^1H NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.5$ Hz), 3.87 (2H, dt, $J = 5.3$ Hz, $J = 1.8$ Hz), 4.26–4.48 (4H, m), 5.11 (1H, ddd, $J_{\text{HHZ}} = 10.5$ Hz, $J = 3.4$ Hz, $J = 1.8$ Hz), 5.20 (1H, ddd, $J_{\text{HHE}} = 17.3$ Hz, $J = 3.4$ Hz, $J = 1.8$ Hz), 5.90 (1H, ddt, $J_{\text{HHE}} = 17.3$ Hz, $J_{\text{HHZ}} = 10.5$ Hz, $J = 5.3$ Hz), 7.13 (2H, dd, $J_{\text{HF}} = 8.5$ Hz, $J = 8.5$ Hz), 7.28–7.35 (2H, m). ^{13}C NMR (75 MHz, CDCl₃) δ : 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 55.9, 65.5 (d, $^2J_{\text{CP}} = 6.9$ Hz), 81.9 (d, $^1J_{\text{CP}} = 176.5$ Hz), 115.3 (d, $^2J_{\text{CF}} = 20.8$ Hz), 116.3, 127.6, 131.0 (d, $^3J_{\text{CF}} = 8.1$ Hz), 134.0, 163.1 (d, $^1J_{\text{CF}} = 249.2$ Hz), 165.2. ^{19}F NMR (282 MHz, CDCl₃) δ : -110.98 to -110.87 (m). ^{31}P NMR (121 MHz, CDCl₃) δ : 10.76. IR (cm⁻¹) ν_{max} : 1019 (P–O), 1052 (P–O), 1229 (P=O), 1507, 2983. MS (ESI, pos): m/z 382.0/383.3/384.0 (M + H⁺, 100/16/64). HRMS: m/z calcd for C₁₅H₂₀Cl₂FNO₃P (M + H)⁺ 382.0536, found 382.0540.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-chlorophenyl)ethyl)phosphonate 8c. 0.63 g (1.91 mmol) of enamine/imine **6c/7c** was converted into 0.74 g of **8c** (1.85 mmol, 97% yield, yellow oil). ^1H

NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.5$ Hz), 3.85–3.88 (2H, m), 4.26–4.48 (4H, m), 5.11 (1H, ddd, $J_{\text{HH,Z}} = 10.4$ Hz, $J = 3.4$ Hz, 1.7 Hz), 5.20 (1H, $J_{\text{HH,E}} = 17.3$ Hz, $J = 3.4$ Hz, $J = 1.8$ Hz), 5.89 (1H, ddt, $J_{\text{HH,E}} = 17.3$ Hz, $J_{\text{HH,Z}} = 10.4$ Hz, $J = 5.2$ Hz), 7.26 (2H, d, $J = 8.5$ Hz), 7.42 (2H, d, $J = 8.5$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 56.0, 65.6 (d, $^2J_{\text{CP}} = 6.9$ Hz), 81.8 (d, $^1J_{\text{CP}} = 177.0$ Hz), 116.5, 128.5, 130.1 (d, $^3J_{\text{CP}} = 5.8$ Hz), 130.4, 134.0, 135.7, 165.1. ³¹P NMR (121 MHz, CDCl₃) δ : 10.65. IR (cm⁻¹) ν_{max} : 1012 (P–O), 1054 (P=O), 1264 (P=O), 1487, 2982. MS (ESI, pos): m/z 398.0/400.0/402.0 (M + H⁺, 100/97/40). HRMS: m/z calcd for C₁₅H₂₀Cl₃NO₃P (M + H)⁺ 398.0241, found 398.0246.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-bromophenyl)ethyl)phosphonate 8d. 0.67 g (1.80 mmol) of enamine/imine 6d/7d was converted into 0.65 g of 8d (1.48 mmol, 82% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.2$ Hz), 3.86–3.87 (2H, m), 4.24–4.48 (4H, m), 5.11 (1H, ddd, $J_{\text{HH,Z}} = 10.2$ Hz, $J = 3.3$ Hz, $J = 1.7$ Hz), 5.20 (1H, ddd, $J_{\text{HH,E}} = 17.3$ Hz, $J = 3.3$ Hz, $J = 1.7$ Hz), 5.90 (1H, ddt, $J_{\text{HH,E}} = 17.3$ Hz, $J_{\text{HH,Z}} = 10.2$ Hz, $J = 5.2$ Hz), 7.20 (2H, d, $J = 8.3$ Hz), 7.58 (2H, d, $J = 8.3$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.6 (d, $^3J_{\text{CP}} = 5.8$ Hz), 56.0, 65.7 (d, $^2J_{\text{CP}} = 6.9$ Hz), 81.7 (d, $^1J_{\text{CP}} = 177.7$ Hz), 116.5, 124.0, 130.5, 130.7, 131.5, 134.1, 165.1. ³¹P NMR (121 MHz, CDCl₃) δ : 10.64. IR (cm⁻¹) ν_{max} : 1010 (P–O), 1054 (P–O), 1260 (P=O), 1484, 2982. MS (ESI, pos): m/z 442.0/444.0/446.0 (M + H⁺, 62/100/45). HRMS: m/z calcd for C₁₅H₂₀BrCl₂NO₃P (M + H)⁺ 441.9736, found 441.9743.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-methoxyphenyl)ethyl)phosphonate 8e. 1.23 g (3.78 mmol) of enamine/imine 6e/7e was converted into 1.37 g 8e (3.48 mmol, 92% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.4$ Hz), 3.85 (3H, s), 3.89 (2H, dt, $J = 5.1$ Hz, $J = 1.7$ Hz), 4.27–4.48 (4H, m), 5.10 (1H, ddd, $J_{\text{HH,Z}} = 10.5$ Hz, $J = 3.6$ Hz, $J = 1.7$ Hz), 5.21 (1H, ddd, $J_{\text{HH,E}} = 17.3$ Hz, $J = 3.6$ Hz, $J = 1.7$ Hz), 5.91 (1H, ddt, $J_{\text{HH,E}} = 17.3$ Hz, $J_{\text{HH,Z}} = 10.5$ Hz, $J = 5.1$ Hz), 6.95 (2H, d, $J = 8.8$ Hz), 7.26 (2H, d, $J = 8.8$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 55.0, 55.5, 65.0 (d, $^2J_{\text{CP}} = 5.8$ Hz), 82.3 (d, $^1J_{\text{CP}} = 176.5$ Hz), 113.3, 115.9, 123.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 130.1, 134.2, 160.1, 165.9. ³¹P NMR (121 MHz, CDCl₃) δ : 11.12. IR (cm⁻¹) ν_{max} : 1020 (P–O), 1055 (P–O), 1245 (P=O), 1509, 2981. MS: m/z (ESI, pos) 394.3/395.3/396.3 (M + H⁺, 100/17/64). HRMS: m/z calcd for C₁₆H₂₃Cl₂NO₄P (M + H)⁺ 394.0736, found 394.0744.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-methylphenyl)ethyl)phosphonate 8f. 1.78 g (5.75 mmol) of enamine/imine 6f/7f was converted into 2.09 g 8f (5.52 mmol, 96% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.37 (6H, t, $J = 6.9$ Hz), 2.39 (3H, s), 3.87 (2H, dt, $J = 5.1$ Hz, $J = 1.7$ Hz), 4.27–4.51 (4H, m), 5.10 (1H, ddd, $J_{\text{HH,Z}} = 10.4$ Hz, $J = 3.4$ Hz, $J = 1.7$ Hz), 5.21 (1H, ddd, $J_{\text{HH,E}} = 17.1$ Hz, $J = 3.4$ Hz, $J = 1.7$ Hz), 5.90 (1H, ddt, $J_{\text{HH,E}} = 17.1$ Hz, $J_{\text{HH,Z}} = 10.4$ Hz, $J = 5.1$ Hz), 7.22 (4H, d, $J = 2.8$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.6 (d, $^3J_{\text{CP}} = 5.8$ Hz), 21.5, 55.9, 65.5 (d, $^2J_{\text{CP}} = 6.9$ Hz), 82.2 (d, $^1J_{\text{CP}} = 176.5$ Hz), 116.3, 128.8, 128.9, 134.5, 139.4, 166.3 (d, $^2J_{\text{CP}} = 2.3$ Hz). ³¹P NMR (121 MHz, CDCl₃) δ : 11.07. IR (cm⁻¹) ν_{max} : 1017 (P–O), 1052 (P–O), 1262 (P=O), 1654, 2982. MS (ESI, pos): m/z 378.3/379.3/380.3 (M + H⁺, 100/18/64). HRMS: m/z calcd for C₁₆H₂₃Cl₂NO₃P (M + H)⁺ 378.0787, found 378.0795.

Diethyl (2-(1,1'-Biphenyl-4-yl)-2-(allylimino)-1,1-dichloroethyl)phosphonate 8g. 1.78 g (5.75 mmol) of enamine/imine 6g/7g was converted into 2.09 g of 8g (5.52 mmol, 90% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.2$ Hz), 3.92 (2H, dt, $J = 5.1$ Hz, $J = 1.8$ Hz), 4.28–4.50 (4H, m), 5.12 (1H, ddd, $J_{\text{HH,Z}} = 10.5$ Hz, $J = 3.4$ Hz, $J = 1.8$ Hz), 5.24 (1H, ddd, $J_{\text{HH,E}} = 17.2$ Hz, $J = 3.4$ Hz, $J = 1.8$ Hz), 5.93 (1H, ddt, $J_{\text{HH,E}} = 17.2$ Hz, $J_{\text{HH,Z}} = 10.5$ Hz, $J = 5.1$ Hz), 7.35–7.49 (5H, m), 7.57–7.71 (4H, m). ¹³C NMR (75 MHz, CDCl₃) δ : 16.6 (d, $^3J_{\text{CP}} = 5.8$ Hz), 56.0, 65.6 (d, $^2J_{\text{CP}} = 6.9$ Hz), 82.1 (d, $^1J_{\text{CP}} = 176.5$ Hz), 116.4, 126.8, 127.2, 127.9, 129.0, 129.5, 130.7 (d, $^3J_{\text{CP}} = 5.8$ Hz), 134.4, 140.2, 142.2, 166.0 (d, $^2J_{\text{CP}} = 2.3$ Hz). ³¹P NMR (121 MHz, CDCl₃) δ : 10.93. IR (cm⁻¹) ν_{max} : 1019 (P–O), 1054 (P–O), 1262 (P=O), 1712, 2982. MS (ESI, pos): m/z 440.3/441.3/442.3 (M + H⁺, 100/23/64). HRMS: m/z calcd for C₂₁H₂₅Cl₂NO₃P (M + H)⁺ 440.0944, found 440.0947.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(3-methoxyphenyl)ethyl)phosphonate 8h. 2.01 g (6.18 mmol) of enamine/imine 6h/7h was converted into 2.41 g of 8h (6.12 mmol, 99% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.2$ Hz), 3.82 (3H, s), 3.88 (2H, dt, $J = 5.3$ Hz, $J = 1.7$ Hz), 4.27–4.49 (4H, m), 5.11 (1H, dd, $J_{\text{HH,Z}} = 10.8$ Hz, $J = 1.7$ Hz), 5.22 (1H, dd, $J_{\text{HH,E}} = 16.8$ Hz, $J = 1.7$ Hz), 5.91 (1H, ddt, $J_{\text{HH,E}} = 16.8$ Hz, $J_{\text{HH,Z}} = 10.8$ Hz, $J = 5.3$ Hz), 6.85–6.91 (2H, m), 6.97 (1H, dd, $J = 8.1$ Hz, $J = 2.2$ Hz), 7.34 (1H, dd, $J = 8.1$ Hz, $J = 8.1$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 55.2, 55.8, 65.3 (d, $^2J_{\text{CP}} = 6.9$ Hz), 81.7 (d, $^1J_{\text{CP}} = 177.7$ Hz), 114.5, 114.8, 116.1, 121.1, 129.2, 132.8 (d, $^3J_{\text{CP}} = 5.8$ Hz), 134.3, 159.1, 165.7. ³¹P NMR (121 MHz, CDCl₃) δ : 10.96. IR (cm⁻¹) ν_{max} : 1019 (P–O), 1264 (P=O), 1578, 2982. MS (ESI, pos): m/z 394.3/395.3/396.3 (M + H⁺, 100/16/64). HRMS: m/z calcd for C₁₆H₂₃Cl₂NO₄P (M + H)⁺ 394.0736, found 394.0743.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-nitrophenyl)ethyl)phosphonate 8i. 1.78 g (5.23 mmol) of enamine/imine 6i/7i was converted and purified by column chromatography into 0.90 g 8i (2.20 mmol, 42% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.39 (6H, t, $J = 7.2$ Hz), 3.86 (2H, d, $J = 5.4$ Hz), 4.27–4.49 (4H, m), 5.15 (1H, d, $J_{\text{HH,Z}} = 11.2$ Hz), 5.20 (1H, d, $J_{\text{HH,E}} = 17.8$ Hz), 5.90 (1H, ddt, $J_{\text{HH,E}} = 17.8$ Hz, $J_{\text{HH,Z}} = 11.2$ Hz, $J = 5.4$ Hz), 7.54 (2H, d, $J = 8.8$ Hz), 8.31 (2H, d, $J = 8.8$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 56.0, 65.7 (d, $^2J_{\text{CP}} = 6.9$ Hz), 81.0 (d, $^1J_{\text{CP}} = 175.4$ Hz), 116.6, 123.2, 130.2, 133.5, 138.2 (d, $^3J_{\text{CP}} = 5.8$ Hz), 148.3, 163.9. ³¹P NMR (121 MHz, CDCl₃) δ : 10.12. IR (cm⁻¹) ν_{max} : 1013 (P–O), 1052 (P–O), 1263 (P=O), 1347 (N–O), 1521 (N–O), 1600, 2980. MS (ESI, pos): m/z 409.0/410.0/411.0 (M + H⁺, 100/16/64). HRMS: m/z calcd for C₁₅H₂₀Cl₂N₂O₅P (M + H)⁺ 409.0481, found 409.0492. Chromatography: hexanes/EtOAc 3/2, $R_f = 0.11$.

Diethyl (2-(Allylimino)-1,1-dichloro-2-(4-cyanophenyl)ethyl)phosphonate 8j. 1.60 g (5.00 mmol) of enamine/imine 6j/7j was converted and purified by column chromatography into 0.86 g 8j (2.20 mmol, 44% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.38 (6H, t, $J = 7.2$ Hz), 3.84 (2H, d, $J = 5.0$ Hz), 4.26–4.48 (4H, m), 5.14 (d, $J_{\text{HH,Z}} = 11.4$ Hz), 5.19 (d, $J_{\text{HH,E}} = 18.0$ Hz), 5.89 (1H, ddt, $J_{\text{HH,E}} = 18.0$ Hz, $J_{\text{HH,Z}} = 11.4$ Hz, $J = 5.0$ Hz), 7.46 (2H, d, $J = 8.3$ Hz), 7.74 (2H, d, $J = 8.3$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 55.8, 65.5 (d, $^2J_{\text{CP}} = 6.9$ Hz), 81.0 (d, $^1J_{\text{CP}} = 176.5$ Hz), 113.3, 116.5, 117.9, 129.8, 131.8, 133.6, 136.2 (d, $^3J_{\text{CP}} = 4.6$ Hz), 164.0. ³¹P NMR (121 MHz, CDCl₃) δ : 9.96. IR (cm⁻¹) ν_{max} : 1016 (P–O), 1052 (P–O), 1264 (P=O), 2232 (C≡N), 2984. MS (ESI, pos): m/z 389.0/390.0/391.0 (M + H⁺, 100/17/64). HRMS: m/z calcd for C₁₆H₂₀Cl₂N₂O₃P (M + H)⁺ 389.0583, found 389.0597. Chromatography: hexanes/EtOAc 3/2, $R_f = 0.10$.

Synthesis of Diethyl (4-Chloro-3-(chloromethyl)-5-phenyl-3,4-dihydro-2H-pyrrol-4-yl)phosphonates 11a–j. In a round-bottom flame-dried flask and under a N₂-atmosphere were dissolved diethyl (2-(allylimino)-1,1-dichloro-2-phenylethyl)phosphonates 8a–j in dry CH₂Cl₂ (1 mL/mmol). Cu(I)Cl (0.4 equiv) and *N,N,N',N',N''*-pentamethyldiethylenetriamine (0.8 equiv) were added, and the reaction mixture was heated to reflux. The reaction progress was monitored using HPLC. After all starting material had been consumed, the reaction mixture was poured into brine and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic phases were washed with water until no more Cu salts were present (blue color of the aqueous phase disappears). The organic layer was dried over MgSO₄ and concentrated in vacuo, and the residue was purified by crystallization or column chromatography. Only the major diastereoisomers could be isolated in pure form.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-phenyl-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11a. 3.42 g (9.39 mmol) of 8a was converted into 11a. 3.18 g of product was obtained in a dr of 90/10 (8.73 mmol, 93% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ : 1.20 (3H, t, $J = 7.2$ Hz), 1.28 (3H, t, $J = 7.2$ Hz), 3.22–3.38 (1H, m), 3.67 (1H, dd, $J = 10.7$ Hz, $J = 10.7$ Hz), 3.96–4.23 (6H, m), 4.45 (1H, dd, $J = 17.1$ Hz, $J = 6.6$ Hz), 7.36–7.44 (3H, m), 8.02 (2H, d, $J = 7.2$ Hz). ¹³C NMR (75 MHz, CDCl₃) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 44.2 (d, $^3J_{\text{CP}} = 2.3$ Hz), 48.6, 63.2 (d, $^3J_{\text{CP}} = 10.4$ Hz), 64.3 (d, $^2J_{\text{CP}} = 6.9$ Hz), 64.7 (d, $^2J_{\text{CP}} = 8.1$ Hz), 71.2 (d, $^1J_{\text{CP}} = 166.1$

H₂), 128.0, 129.3, 130.7, 132.8, 169.1 (d, ²J_{CP} = 2.3 Hz). ³¹P NMR (121 MHz, CDCl₃) δ: 17.11. IR (cm⁻¹) ν_{max}: 1012 (P–O), 1043 (P–O), 1263 (P=O), 1606, 2981. MS (ESI, pos): *m/z* calcd for C₁₅H₂₁Cl₂NO₃P (M + H)⁺ 364.0631, found 364.0636. Chromatography: hexanes/EtOAc 1/1, R_f = 0.4.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-fluorophenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11b. 3.00 g (7.82 mmol) of **8b** was converted into **11b**. After column chromatography, 1.77 g of product was obtained in a dr of 92/8 (4.61 mmol, 59% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.20 (3H, t, J = 7.2 Hz), 1.31 (3H, t, J = 7.2 Hz), 3.23–3.36 (1H, m), 3.66 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.96–4.19 (6H, m), 4.43 (1H, ddd, J = 17.1 Hz, J = 7.2 Hz, ⁴J_{HP} = 1.7 Hz), 7.07 (2H, dd, J = 8.8 Hz, ³J_{HF} = 8.8 Hz), 8.10 (2H, dd, J = 8.8 Hz, ⁴J_{FH} = 5.5 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 16.2 (d, ³J_{CP} = 5.8 Hz), 44.1 (d, ³J_{CP} = 2.3 Hz), 48.4, 63.1 (d, ³J_{CP} = 9.2 Hz), 64.5 (d, ²J_{CP} = 12.1 Hz), 64.6 (d, ²J_{CP} = 12.1 Hz), 71.1 (d, ²J_{CP} = 165.0 Hz), 114.9 (d, ²J_{CF} = 21.9 Hz), 128.7 (d, ⁴J_{CF} = 3.5 Hz), 131.6 (d, ³J_{CF} = 8.1 Hz), 164.2 (d, ¹J_{CF} = 251.22 Hz), 167.7. ¹⁹F NMR (282 MHz, CDCl₃) δ: -109.43 to -109.32 (m). ³¹P NMR (121 MHz, CDCl₃) δ: 17.08. IR (cm⁻¹) ν_{max}: 1012 (P–O), 1039 (P–O), 1263 (P=O), 1509, 2980. MS (ESI, pos): *m/z* calcd for C₁₅H₂₀Cl₂FNO₃P (M + H)⁺ 382.0536, found 382.0543. Chromatography: hexanes/EtOAc 4/1, R_f = 0.15.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-chlorophenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11c. 0.70 g (1.76 mmol) of **8c** was converted into **11c**. After column chromatography, 0.51 g of product was obtained in a dr of 90/10 (1.28 mmol, 73% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.21 (3H, t, J = 7.2 Hz), 1.31 (3H, t, J = 7.2 Hz), 3.22–3.36 (1H, m), 3.65 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.94–4.23 (6H, m), 4.43 (1H, ddd, J = 17.1 Hz, J = 7.2 Hz, ⁴J_{HP} = 1.7 Hz), 7.37 (2H, d, J = 8.8 Hz), 8.02 (2H, d, J = 8.8 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 16.3 (d, ³J_{CP} = 5.8 Hz), 16.4 (d, ³J_{CP} = 4.6 Hz), 44.1 (d, ³J_{CP} = 3.5 Hz), 48.4, 63.2 (d, ³J_{CP} = 9.2 Hz), 64.5 (d, ²J_{CP} = 6.9 Hz), 64.7 (d, ²J_{CP} = 6.9 Hz), 71.1 (d, ¹J_{CP} = 165.0 Hz), 128.2, 130.8, 131.0, 136.9, 167.8. ³¹P NMR (121 MHz, CDCl₃) δ: 17.06. IR (cm⁻¹) ν_{max}: 1012 (P–O), 1041 (P–O), 1263 (P=O), 1491, 2982. MS (ESI, pos): *m/z* calcd for C₁₅H₂₀Cl₃NO₃P (M + H)⁺ 398.0241, found 398.0249. Chromatography: hexanes/EtOAc 7/3, R_f = 0.21.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-bromophenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11d. 0.65 g (1.47 mmol) of **8d** was converted into **11d**. After column chromatography, 0.28 g of product was obtained in a dr of 89/11 (0.63 mmol, 43% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.12 (3H, t, J = 7.2 Hz), 1.22 (3H, t, J = 7.2 Hz), 3.14–3.27 (1H, m), 3.56 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.88–4.13 (6H, m), 4.33 (1H, ddd, J = 17.2 Hz, J = 7.0 Hz, ⁴J_{HP} = 1.7 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.88 (2H, d, J = 8.8 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 16.3 (d, ³J_{CP} = 5.8 Hz), 16.4 (d, ³J_{CP} = 5.8 Hz), 44.1 (d, ³J_{CP} = 3.5 Hz), 48.4, 63.2 (d, ³J_{CP} = 9.2 Hz), 64.5 (d, ²J_{CP} = 6.9 Hz), 64.7 (d, ²J_{CP} = 6.9 Hz), 71.1 (d, ¹J_{CP} = 165.0 Hz), 125.4, 131.0, 131.1, 131.4, 167.8. ³¹P NMR (121 MHz, CDCl₃) δ: 16.97. IR (cm⁻¹) ν_{max}: 1010 (P–O), 1038 (P–O), 1266 (P=O), 1394, 2978. MS (ESI, pos): *m/z* calcd for C₁₅H₂₀BrCl₂NO₃P (M + H)⁺ 441.9736, found 441.9737. Chromatography: hexanes/EtOAc 7/3, R_f = 0.19.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-methoxyphenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11e. 1.11 g (2.82 mmol) of **8e** was converted into **11e**. After column chromatography, 0.50 g of product was obtained in a dr of 85/15 (1.27 mmol, 45% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.19 (3H, t, J = 7.2 Hz), 1.31 (3H, t, J = 7.2 Hz), 3.21–3.35 (1H, m), 3.64 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.81 (3H, s), 3.91–4.22 (6H, m), 4.39 (1H, ddd, J = 17.1 Hz, J = 7.2 Hz, ⁴J_{HP} = 1.7 Hz), 6.89 (2H, d, J = 9.4 Hz), 8.08 (2H, d, J = 9.4 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 16.2 (d, ³J_{CP} = 5.8 Hz), 16.4 (d, ³J_{CP} = 5.8 Hz), 44.3 (d, ³J_{CP} = 3.5 Hz), 48.4, 55.2, 62.8 (d, ³J_{CP} = 9.2 Hz), 64.3 (d, ²J_{CP} = 6.9 Hz), 64.5 (d, ²J_{CP} = 6.9 Hz), 71.1 (d, ¹J_{CP} = 163.8 Hz), 113.2, 124.8, 131.0, 161.5, 167.8 (d, ²J_{CP} = 2.3 Hz). ³¹P NMR (121 MHz, CDCl₃) δ: 17.48. IR (cm⁻¹) ν_{max}: 1012 (P–O), 1177 (P–O), 1252 (P=O), 1513, 1606, 2978. MS (ESI, pos): *m/z*

394.0/395.0/396.0 (M + H)⁺, 100/18/64). HRMS: *m/z* calcd for C₁₆H₂₃Cl₂NO₄P (M + H)⁺ 394.0736, found 394.0740. Chromatography: hexanes/EtOAc 3/2, R_f = 0.23.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-methylphenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11f. 1.82 g (4.81 mmol) of **8f** was converted into **11f**. After column chromatography, 0.47 g of product was obtained in a dr of 95/5 (1.25 mmol, 26% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.20 (3H, t, J = 7.2 Hz), 1.30 (3H, t, J = 7.2 Hz), 2.37 (3H, s), 3.19–3.37 (1H, m), 3.65 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.94–4.23 (6H, m), 4.42 (1H, ddd, J = 17.1 Hz, J = 7.2 Hz, ⁴J_{HP} = 1.7 Hz), 7.19 (2H, d, J = 8.3 Hz), 7.95 (2H, d, J = 8.3 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 16.3 (d, ³J_{CP} = 5.8 Hz), 16.5 (d, ³J_{CP} = 5.8 Hz), 21.6, 44.3 (d, ³J_{CP} = 2.3 Hz), 48.5, 63.0 (d, ³J_{CP} = 9.2 Hz), 64.4 (d, ²J_{CP} = 6.9 Hz), 64.7 (d, ²J_{CP} = 6.9 Hz), 71.2 (d, ¹J_{CP} = 163.8 Hz), 128.7, 129.3, 129.7, 141.0, 168.8. ³¹P NMR (121 MHz, CDCl₃) δ: 17.36. IR (cm⁻¹) ν_{max}: 1014 (P–O), 1096 (P–O), 1264 (P=O), 1606, 2359, 2981. MS (ESI, pos): *m/z* calcd for C₁₆H₂₃Cl₂NO₃P (M + H)⁺ 378.0787, found 378.0782. Chromatography: hexanes/EtOAc 1/1, R_f = 0.47.

Diethyl (cis-5-([1,1'-Biphenyl]-4-yl)-4-chloro-3-(chloromethyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11g. 1.15 g (2.61 mmol) of **8g** was converted into **11g**. After column chromatography, 0.42 g of product was obtained in a dr of 96/4 (0.97 mmol, 37% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.22 (3H, t, J = 7.0 Hz), 1.31 (3H, t, J = 7.0 Hz), 3.25–3.40 (1H, m), 3.68 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 4.00–4.21 (6H, m), 4.47 (1H, ddd, J = 17.1 Hz, J = 6.9 Hz, ⁴J_{HP} = 1.9 Hz), 7.35–7.47 (3H, m), 7.62–7.65 (4H, m), 8.14–8.18 (2H, m). ¹³C NMR (75 MHz, CDCl₃) δ: 16.4 (d, ³J_{CP} = 5.8 Hz), 16.5 (d, ³J_{CP} = 5.8 Hz), 44.3, 48.5, 63.3 (d, ³J_{CP} = 10.4 Hz), 64.5 (d, ²J_{CP} = 6.9 Hz), 64.7 (d, ²J_{CP} = 6.9 Hz), 71.3 (d, ¹J_{CP} = 165.0 Hz), 126.6, 127.2, 127.9, 129.0, 129.9, 131.5, 140.3, 143.3, 168.5 (d, ²J_{CP} = 2.3 Hz). ³¹P NMR (121 MHz, CDCl₃) δ: 17.27. IR (cm⁻¹) ν_{max}: 1014 (P–O), 1043 (P–O), 1263 (P=O), 1602, 2980. MS (ESI, pos): *m/z* calcd for C₂₁H₂₅Cl₂NO₃P (M + H)⁺ 440.0944, found 440.0949. Chromatography: hexanes/EtOAc 7/3, R_f = 0.29.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(3-methoxyphenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11h. 2.11 g (5.35 mmol) of **8h** was converted into **11h**. After column chromatography, 1.27 g of product was obtained in a dr of 93/7 (3.21 mmol, 60% yield, brown oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.21 (3H, t, J = 7.2 Hz), 1.29 (3H, t, J = 7.2 Hz), 3.24–3.36 (1H, m), 3.66 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.84, 3.96–4.18 (6H, m), 4.45 (1H, dd, J = 17.1 Hz, J = 7.2 Hz), 6.99 (1H, d, J = 8.1 Hz), 7.30 (1H, dd, J = 8.1 Hz, J = 8.1 Hz), 7.63–7.66 (2H, m). ¹³C NMR (75 MHz, CDCl₃) δ: 16.3 (d, ³J_{CP} = 5.8 Hz), 16.4 (d, ³J_{CP} = 5.8 Hz), 44.2 (d, ³J_{CP} = 2.3 Hz), 48.6, 55.4, 63.1 (d, ³J_{CP} = 10.4 Hz), 64.3 (d, ²J_{CP} = 10.4 Hz), 64.7 (d, ²J_{CP} = 10.4 Hz), 71.2 (d, ¹J_{CP} = 165.0 Hz), 114.1, 117.0, 121.7, 129.0, 133.8, 159.1, 168.8. ³¹P NMR (121 MHz, CDCl₃) δ: 17.21. IR (cm⁻¹) ν_{max}: 1013 (P–O), 1263 (P=O), 1578, 2981. MS (ESI, pos): *m/z* calcd for C₁₆H₂₃Cl₂NO₄P (M + H)⁺ 394.0736, found 394.0732. Chromatography: hexanes/EtOAc 3/2, R_f = 0.29.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-nitrophenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate 11i. 0.60 g (1.47 mmol) of **8i** was converted into **11i**. After one crystallization, 0.14 g of product was obtained in a dr of 93/7 (0.34 mmol, 23% yield, orange needles). ¹H NMR (300 MHz, CDCl₃) δ: 1.22 (3H, t, J = 7.2 Hz), 1.32 (3H, t, J = 7.2 Hz), 3.25–3.40 (1H, m), 3.67 (1H, dd, J = 10.5 Hz, J = 10.5 Hz), 3.97–4.25 (6H, m), 4.50 (1H, dd, J = 17.6 Hz, J = 7.2 Hz), 8.25 (4H, s). ¹³C NMR (75 MHz, CDCl₃) δ: 16.3 (d, ³J_{CP} = 5.8 Hz), 16.5 (d, ³J_{CP} = 5.8 Hz), 43.9 (d, ³J_{CP} = 2.3 Hz), 48.4, 63.6 (d, ³J_{CP} = 9.2 Hz), 64.8 (d, ²J_{CP} = 6.9 Hz), 71.1 (d, ¹J_{CP} = 163.8 Hz), 123.0, 130.5, 138.5, 149.0, 167.4. ³¹P NMR (121 MHz, CDCl₃) δ: 16.59. IR (cm⁻¹) ν_{max}: 1011 (P–O), 1041 (P–O), 1266 (P=O), 1342 (N–O), 1518 (N–O), 1594, 2980. MS (ESI, pos): *m/z* calcd for C₁₅H₂₀Cl₂N₂O₅P (M + H)⁺ 409.0481, found 409.0483. Melting point range: 108.0–109.0 °C.

Diethyl (cis-4-Chloro-3-(chloromethyl)-5-(4-cyanophenyl)-3,4-dihydro-2H-pyrrol-4-yl)phosphonate **11j**. 0.85 g (2.18 mmol) of **8j** was converted into **11j**. After one crystallization, 0.12 g of product was obtained in a dr of 95/5 (0.31 mmol, 14% yield, transparent crystals). ^1H NMR (300 MHz, CDCl_3) δ : 1.21 (3H, t, $J = 7.2$ Hz), 1.32 (3H, t, $J = 6.9$ Hz), 3.24–3.37 (1H, m), 3.66 (1H, dd, $J = 10.5$ Hz, $J = 10.5$ Hz), 3.96–4.24 (6H, m), 4.48 (1H, dd, $J = 17.6$ Hz, $J = 7.2$ Hz), 7.69 (2H, d, $J = 8.3$ Hz), 8.19 (2H, d, $J = 8.3$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.5 (d, $^3J_{\text{CP}} = 4.6$ Hz), 44.0 (d, $^3J_{\text{CP}} = 2.3$ Hz), 48.4, 63.6 (d, $^3J_{\text{CP}} = 9.2$ Hz), 64.8 (d, $^2J_{\text{CP}} = 6.9$ Hz), 71.1 (d, $^1J_{\text{CP}} = 166.1$ Hz), 114.2, 118.5, 130.1, 131.7, 136.7, 167.6. ^{31}P NMR (121 MHz, CDCl_3) δ : 16.67. IR (cm^{-1}) ν_{max} : 1011 (P–O), 1039 (P=O), 1266 (P=O), 2230 (C≡N), 2984. MS (ESI, pos): m/z 389.0/390.0/391.0 ($\text{M} + \text{H}^+$, 100/17/64). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{20}\text{Cl}_2\text{N}_2\text{O}_3\text{P}$ ($\text{M} + \text{H}^+$)⁺ 389.0583, found 389.0595. Melting point range: 111.0–112.5 °C.

Synthesis of Diethyl (2-Phenyl-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonates 14a–j. In a round-bottom flame-dried flask and under a N_2 -atmosphere were dissolved diethyl (cis-4-chloro-3-(chloromethyl)-5-phenyl-3,4-dihydro-2H-pyrrol-4-yl)phosphonates **11a–j** in dry THF (1 mL/mmol). The solution was cooled to -78 °C, and $n\text{-BuLi}$ (1.2 equiv, however for **14j** 2.2 equiv was used) was added in a dropwise fashion. The reaction mixture was kept at -78 °C for 2 h and was then slowly warmed to room temperature. Water was added, and the solution was extracted with diethyl ether (3×10 mL). After the combined organic layers were dried over MgSO_4 , the solvent was removed in vacuo and the residue was purified using column chromatography.

Diethyl (2-Phenyl-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14a**. 2.50 g (6.86 mmol) of **11a** was converted into **14a**. After column chromatography, 1.53 g of product was obtained (5.21 mmol, 76% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.84–0.90 (1H, ~q), 1.17 (3H, t, $J = 7.2$ Hz), 1.20 (3H, t, $J = 7.2$ Hz), 1.76 (1H, ddd, $^3J_{\text{HP}} = 14.6$ Hz, $J = 8.5$ Hz, $J = 4.7$ Hz), 2.58–2.69 (1H, m), 3.91–4.03 (4H, m), 4.10 (2H, ~t), 7.37–7.44 (3H, m), 7.91 (2H, d, $J = 6.6$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.2 (d, $^3J_{\text{CP}} = 4.6$ Hz), 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 19.2, 28.7, 34.0 (d, $^1J_{\text{CP}} = 199.6$ Hz), 61.3 (d, $^3J_{\text{CP}} = 3.5$ Hz), 62.2 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.4 (d, $^2J_{\text{CP}} = 6.9$ Hz), 128.0, 128.7, 130.5, 134.1, 173.1 (d, $^2J_{\text{CP}} = 8.1$ Hz). ^{31}P NMR (121 MHz, CDCl_3) δ : 22.91. IR (cm^{-1}) ν_{max} : 1022 (P–O), 1049 (P–O), 1247 (P=O), 1596, 2982. MS (ESI, pos): m/z 294.3/295.3 ($\text{M} + \text{H}^+$, 100/16). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_3\text{P}$ ($\text{M} + \text{H}^+$)⁺ 294.1254, found 294.1264. Chromatography: EtOAc, $R_f = 0.06$.

Diethyl (2-(4-Fluorophenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14b**. 0.18 g (0.47 mmol) of **11b** was converted into **14b**. After column chromatography, 72 mg of product was obtained (0.23 mmol, 49% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.83–0.89 (1H, m), 1.18 (3H, t, $J = 7.5$ Hz), 1.21 (3H, t, $J = 7.5$ Hz), 1.75 (1H, ddd, $^3J_{\text{HP}} = 14.5$ Hz, $J = 8.4$ Hz, $J = 4.3$ Hz), 2.54–2.69 (1H, m), 3.93–4.05 (4H, m), 4.08 (2H, ~t), 7.09 (2H, dd, $J = 8.8$ Hz, $^3J_{\text{FH}} = 8.8$ Hz), 7.94 (2H, dd, $J = 8.8$ Hz, $^4J_{\text{HF}} = 5.5$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.3 (d, $^3J_{\text{CP}} = 5.2$ Hz), 16.3 (d, $^3J_{\text{CP}} = 5.2$ Hz), 19.2, 28.9, 33.9 (d, $^1J_{\text{CP}} = 200.8$ Hz), 61.2 (d, $^3J_{\text{CP}} = 3.5$ Hz), 62.3 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.5 (d, $^2J_{\text{CP}} = 5.8$ Hz), 115.1 (d, $^2J_{\text{CF}} = 21.9$ Hz), 130.3 (d, $^4J_{\text{CF}} = 2.3$ Hz), 130.9 (d, $^3J_{\text{CF}} = 8.1$ Hz), 164.3 (d, $^1J_{\text{CF}} = 250.4$ Hz), 172.0 (d, $^2J_{\text{CP}} = 8.1$ Hz). ^{19}F NMR (282 MHz, CDCl_3) δ : -109.92 to -109.82 (m). ^{31}P NMR (121 MHz, CDCl_3) δ : 22.83. IR (cm^{-1}) ν_{max} : 1019 (P–O), 1047 (P–O), 1229 (P=O), 1510, 2984. MS (ESI, pos): m/z 312.3/313.3 ($\text{M} + \text{H}^+$, 100/17). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{20}\text{FNO}_3\text{P}$ ($\text{M} + \text{H}^+$)⁺ 312.1159, found 312.1165. Chromatography: EtOAc, $R_f = 0.09$.

Diethyl (2-(4-Chlorophenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14c**. 0.15 g (0.38 mmol) of **11c** was converted into **14c**. After column chromatography, 41 mg of product was obtained (0.13 mmol, 33% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.81–0.88 (1H, m), 1.18 (3H, t, $J = 7.2$ Hz), 1.22 (3H, t, $J = 7.2$ Hz), 1.75 (1H, ddd, $^3J_{\text{HP}} = 14.5$ Hz, $J = 8.4$ Hz, $J = 4.4$ Hz), 2.58–2.69 (1H, m), 3.93–4.05 (4H, m), 4.09 (2H, ~t), 7.38 (2H, d, $J = 8.5$ Hz), 7.87 (2H, d, $J = 8.5$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 19.2, 28.9, 33.9 (d, $^1J_{\text{CP}} = 199.6$ Hz), 61.3

(d, $^3J_{\text{CP}} = 3.5$ Hz), 62.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 62.6 (d, $^3J_{\text{CP}} = 5.8$ Hz), 128.3, 130.2, 132.5, 136.7, 172.1 (d, $^2J_{\text{CP}} = 8.1$ Hz). ^{31}P NMR (121 MHz, CDCl_3) δ : 22.74. IR (cm^{-1}) ν_{max} : 1020 (P–O), 1048 (P–O), 1247 (P=O), 1596, 2984. MS (ESI, pos): m/z 328.3/330.3/329.3 ($\text{M} + \text{H}^+$, 100/32/17). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{20}\text{ClNO}_3\text{P}$ ($\text{M} + \text{H}^+$)⁺ 328.0864, found 328.0868. Chromatography: EtOAc, $R_f = 0.09$.

Diethyl (2-(4-Methoxyphenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14e**. 1.13 g (2.87 mmol) of **11e** was converted into **14e**. After column chromatography, 0.47 g of product was obtained (1.46 mmol, 51% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.81–0.87 (1H, m), 1.20 (6H, t, $J = 7.5$ Hz), 1.74 (1H, ddd, $^3J_{\text{HP}} = 14.6$ Hz, $J = 8.5$ Hz, $J = 4.4$ Hz), 2.56–2.66 (1H, m), 3.84 (3H, s), 3.93–4.03 (4H, m), 4.06 (2H, m), 6.91 (2H, d, $J = 8.8$ Hz), 7.91 (2H, d, $J = 8.8$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 15.9 (d, $J = 4.6$ Hz), 16.0 (d, $J = 4.6$ Hz), 18.7, 28.5, 33.4 (d, $^1J_{\text{CP}} = 199.6$ Hz), 54.9, 60.5 (d, $^3J_{\text{CP}} = 3.5$ Hz), 61.8 (d, $^2J_{\text{CP}} = 6.9$ Hz), 62.1 (d, $^2J_{\text{CP}} = 6.9$ Hz), 113.0, 126.5, 130.2, 161.2, 171.8 (d, $^2J_{\text{CP}} = 6.9$ Hz). ^{31}P NMR (121 MHz, CDCl_3) δ : 23.26. IR (cm^{-1}) ν_{max} : 1018 (P–O), 1174 (P–O), 1249 (P=O), 1514, 1607, 2918, 3429. MS (ESI, pos): m/z 324.3/325.3 ($\text{M} + \text{H}^+$, 100/17). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{23}\text{NO}_4\text{P}$ ($\text{M} + \text{H}^+$)⁺ 324.1359, found 324.1359. Chromatography: EtOAc, $R_f = 0.08$.

Diethyl (2-(4-Methylphenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14f**. 2.70 g (7.14 mmol) of **11f** was converted into **14f**. After column chromatography, 1.18 g of product was obtained (3.86 mmol, 54% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.83–0.88 (1H, m), 1.14–1.26 (6H, m), 1.74 (1H, ddd, $^3J_{\text{HP}} = 14.3$ Hz, $J = 8.3$ Hz, $J = 4.4$ Hz), 2.38 (3H, s), 2.61 (1H, m), 3.92–4.04 (4H, m), 4.04–4.12 (2H, m), 7.20 (d, $J = 8.0$ Hz), 7.82 (d, $J = 8.0$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.2 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 19.2, 21.5, 28.7, 33.9 (d, $^1J_{\text{CP}} = 201.9$ Hz), 61.1 (d, $^3J_{\text{CP}} = 3.5$ Hz), 62.2 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.4 (d, $^2J_{\text{CP}} = 5.8$ Hz), 128.7, 131.3, 140.7, 173.0 (d, $^2J_{\text{CP}} = 8.1$ Hz). ^{31}P NMR (121 MHz, CDCl_3) δ : 23.18. IR (cm^{-1}) ν_{max} : 1024 (P–O), 1050 (P–O), 1248 (P=O), 1594, 2922. MS (ESI, pos): m/z 308.3/309.3 ($\text{M} + \text{H}^+$, 100/18). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{23}\text{NO}_3\text{P}$ ($\text{M} + \text{H}^+$)⁺ 308.1410, found 308.1411. Chromatography: EtOAc, $R_f = 0.09$.

Diethyl (2-([1,1'-Biphenyl]-4-yl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14g**. 1.84 g (4.18 mmol) of **11g** was converted into **14g**. After column chromatography, 0.56 g of product was obtained (1.50 mmol, 30% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.85–0.92 (1H, ~q), 1.21 (6H, t, $J = 7.6$ Hz), 1.78 (1H, ddd, $^3J_{\text{HP}} = 14.2$ Hz, $J = 8.9$ Hz, $J = 4.8$ Hz), 2.58–2.71 (1H, m), 3.95–4.07 (4H, m), 4.10–4.13 (2H, ~t), 7.34–7.38 (1H, m), 7.45 (2H, dd, $J = 7.3$ Hz, $J = 7.3$ Hz), 7.64 (4H, d, $J = 8.3$ Hz), 8.01 (2H, d, $J = 7.3$ Hz). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.4 (d, $^3J_{\text{CP}} = 5.8$ Hz), 19.3, 28.8, 33.9 (d, $^1J_{\text{CP}} = 199.6$ Hz), 61.3 (d, $^3J_{\text{CP}} = 3.5$ Hz), 62.3 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.5 (d, $^2J_{\text{CP}} = 5.8$ Hz), 126.7, 127.2, 127.8, 128.9, 129.3, 133.0, 140.5, 143.2, 172.8 (d, $^2J_{\text{CP}} = 8.1$ Hz). ^{31}P NMR (121 MHz, CDCl_3) δ : 23.02. IR (cm^{-1}) ν_{max} : 1021 (P–O), 1045 (P–O), 1246 (P=O), 1594, 2982. MS (ESI, pos): m/z 370.3/371.3 ($\text{M} + \text{H}^+$, 100/23). HRMS: m/z calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_3\text{P}$ ($\text{M} + \text{H}^+$)⁺ 370.1567, found 370.1563. Chromatography: EtOAc, $R_f = 0.10$.

Diethyl (2-(3-Methoxyphenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate **14h**. 1.72 g (4.36 mmol) of **11h** was converted into **14h**. After column chromatography, 1.01 g of product was obtained (3.14 mmol, 72% yield, brown oil). ^1H NMR (300 MHz, CDCl_3) δ : 0.86 (1H, ~q), 1.18 (3H, t, $J = 7.3$ Hz), 1.20 (3H, t, $J = 7.3$ Hz), 1.75 (1H, ddd, $^3J_{\text{HP}} = 14.7$ Hz, $J = 8.4$ Hz, $J = 4.3$ Hz), 2.57–2.69 (1H, m), 3.86 (3H, s), 3.93–4.04 (4H, m), 4.08 (2H, ~t), 6.99 (1H, dd, $J = 8.1$ Hz, $J = 2.8$ Hz), 7.31 (1H, dd, $J = 8.1$ Hz, $J = 8.1$ Hz), 7.48–7.54 (2H, m). ^{13}C NMR (75 MHz, CDCl_3) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 19.2, 28.9, 34.0 (d, $^1J_{\text{CP}} = 200.8$ Hz), 55.4, 61.3 (d, $^3J_{\text{CP}} = 3.5$ Hz), 62.2 (d, $^2J_{\text{CP}} = 6.9$ Hz), 62.5 (d, $^2J_{\text{CP}} = 6.9$ Hz), 113.3, 117.1, 121.3, 129.0, 135.3, 152.3, 173.0 (d, $^2J_{\text{CP}} = 6.9$ Hz). ^{31}P NMR (121 MHz, CDCl_3) δ : 22.97. IR (cm^{-1}) ν_{max} : 1018 (P–O), 1238 (P=O), 1327, 1575, 2981. MS (ESI, pos): m/z 324.3/325.3 ($\text{M} + \text{H}^+$, 100/16). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{23}\text{NO}_4\text{P}$ ($\text{M} + \text{H}^+$)⁺ 324.1359, found 324.1361. Chromatography: EtOAc, $R_f = 0.18$.

Diethyl (2-(4-Nitrophenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate 14i. 0.38 g (0.94 mmol) of **11i** was converted into **14i**. After column chromatography, 64 mg of product was obtained (0.19 mmol, 20% yield, brown oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 0.87–0.93 (1H, m), 1.19 (3H, t, $J = 6.9$ Hz), 1.23 (3H, t, $J = 7.2$ Hz), 1.80 (1H, ddd, $^3J_{\text{HP}} = 13.9$ Hz, $J = 8.1$ Hz, $J = 4.3$ Hz), 2.69 (1H, m), 3.95–4.08 (4H, m), 4.16 (2H, ~t), 8.10 (2H, d, $J = 8.5$ Hz), 8.27 (2H, d, $J = 8.5$ Hz). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 16.3 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.4 (d, $^3J_{\text{CP}} = 6.9$ Hz), 19.3, 29.0, 34.1 (d, $^1J_{\text{CP}} = 201.9$ Hz), 61.9, 62.5 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.7 (d, $^2J_{\text{CP}} = 5.8$ Hz), 123.3, 129.8, 139.9, 150.0, 171.5 (d, $^2J_{\text{CP}} = 9.2$ Hz). $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 22.17. IR (cm^{-1}) ν_{max} : 1018 (P–O), 1047 (P–O), 1248 (P=O), 1325 (N–O), 1519 (N–O), 1586, 2983. MS (ESI, pos): m/z 339.3/340.3 ($\text{M} + \text{H}^+$, 100/16). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_5\text{P}$ ($\text{M} + \text{H}^+$) 339.1104, found 339.1114. Chromatography: EtOAc, $R_f = 0.21$.

Diethyl (2-(4-Pentanoylphenyl)-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonate 14j. 0.44 g (1.13 mmol) of **11j** was converted into **14j**. After column chromatography, 0.15 g of product was obtained (0.41 mmol, 36% yield, brown oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 0.86–0.92 (1H, m), 0.96 (3H, t, $J = 7.4$ Hz), 1.17 (3H, t, $J = 7.3$ Hz), 1.21 (3H, t, $J = 7.3$ Hz), 1.41 (2H, sext, $J = 7.4$ Hz), 1.73 (2H, quint, $J = 7.4$ Hz), 1.78–1.83 (1H, m), 2.61–2.71 (1H, m), 2.99 (2H, t, $J = 7.4$ Hz), 3.92–4.05 (4H, m), 4.14 (2H, d, $J = 3.9$ Hz), 7.99 (4H, s). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 14.0, 16.3 (d, $^3J_{\text{CP}} = 6.9$ Hz), 16.4 (d, $^3J_{\text{CP}} = 6.9$ Hz), 19.2, 22.5, 26.4, 28.9, 34.1 (d, $^1J_{\text{CP}} = 200.8$ Hz), 38.6, 61.7 (d, $^3J_{\text{CP}} = 3.5$ Hz), 62.4 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.6 (d, $^2J_{\text{CP}} = 5.8$ Hz), 127.8, 129.0, 138.1, 138.3, 172.5 (d, $^2J_{\text{CP}} = 9.2$ Hz), 200.3. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 22.56. IR (cm^{-1}) ν_{max} : 1024 (P–O), 1249 (P=O), 1684 (C=O), 2931. MS (ESI, pos): m/z 378.3/379.3 ($\text{M} + \text{H}^+$, 100/16). HRMS: m/z calcd for $\text{C}_{20}\text{H}_{29}\text{NO}_4\text{P}$ ($\text{M} + \text{H}^+$) 378.1829, found 378.1835. Chromatography: EtOAc, $R_f = 0.16$.

Synthesis of Diethyl (2-Phenyl-3-azabicyclo[3.1.0]hexan-1-yl)phosphonates 1a–j. Diethyl (2-phenyl-3-azabicyclo[3.1.0]hex-2-en-1-yl)phosphonates **14a–j** were dissolved in MeOH (1 mL/mmol). Then NaCNBH_3 (1.05 equiv) and HOAc (1.05 equiv) were added. The reaction progress was monitored using HPLC. After all starting material had been consumed, the reaction mixture was poured into aqueous NaHCO_3 and extracted with diethyl ether (3×10 mL). The combined organic layers were dried over MgSO_4 and concentrated in vacuo. All compounds were obtained in a dr of $\geq 99/1$.

Diethyl ((1S*,2S*,5R*)-2-Phenyl-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1a. 87 mg (0.32 mmol) of **14a** was converted into **1a**. 79 mg of product was obtained (0.27 mmol, 84% yield, yellow oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.00 (3H, t, $J = 7.2$ Hz), 1.19–1.32 (3H, t, $J = 7.2$ Hz, 2H, m), 1.97–2.06 (1H, m), 2.09 (1H, br s), 3.16 (2H, s), 3.64–4.05 (4H, m), 4.52 (d, $^3J_{\text{HP}} = 3.9$ Hz), 7.27–7.34 (3H, m), 7.48 (2H, d, $J = 6.6$ Hz). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.6, 16.1 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 24.8, 25.8 (d, $^1J_{\text{CP}} = 198.5$ Hz), 47.7 (d, $^3J_{\text{CP}} = 3.5$ Hz), 61.7 (d, $^2J_{\text{CP}} = 5.8$ Hz), 61.9 (d, $^2J_{\text{CP}} = 6.9$ Hz), 63.0 (d, $^2J_{\text{CP}} = 10.4$ Hz), 127.9, 128.0, 128.2, 139.6. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 28.51. IR (cm^{-1}) ν_{max} : 1019 (P–O), 1056 (P–O), 1234 (P=O), 1366, 2981, 3310. MS (ESI, pos): m/z 296.3/297.3 ($\text{M} + \text{H}^+$, 100/16). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{23}\text{NO}_3\text{P}$ ($\text{M} + \text{H}^+$) 296.1410, found 296.1416.

Diethyl ((1S*,2S*,5R*)-2-(4-Fluorophenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1b. 0.48 g (1.53 mmol) of **14b** was converted into **1b**. 0.36 g of product was obtained (1.13 mmol, 74% yield, yellow oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.02 (3H, t, $J = 7.2$ Hz), 1.25 (3H, t, $J = 7.2$ Hz, 2H, m), 1.89–2.01 (1H, m), 2.43 (1H, br s), 3.11 (2H, br s), 3.66–4.04 (4H, m), 4.47 (1H, d, $^3J_{\text{HP}} = 4.4$ Hz), 6.98 (2H, dd, $J = 8.6$ Hz, $^3J_{\text{HP}} = 8.6$ Hz), 7.45 (2H, dd, $J = 8.6$ Hz, $^4J_{\text{HP}} = 5.5$). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.0, 15.9 (d, $^3J_{\text{CP}} = 6.9$ Hz), 16.3 (d, $^3J_{\text{CP}} = 6.9$ Hz), 24.6, 25.7 (d, $J = 198.5$ Hz), 47.3 (d, $^3J_{\text{CP}} = 3.5$ Hz), 61.5 (d, $J = 6.9$ Hz), 61.7 (d, $J = 6.9$ Hz), 61.9 (d, $^2J_{\text{CP}} = 10.4$ Hz), 114.6 (d, $^2J_{\text{CP}} = 21.9$ Hz), 129.4 (d, $^3J_{\text{CP}} = 8.1$ Hz), 135.6 (d, $^2J_{\text{CP}} = 2.3$ Hz), 162.2 (d, $^1J_{\text{CF}} = 245.8$ Hz). $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : –115.20 to –115.11. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 28.42. IR (cm^{-1}) ν_{max} : 1021 (P–O), 1058 (P–O), 1231 (P=O), 1508, 2982. MS (ESI, pos): m/z 314.3/315.3 ($\text{M} + \text{H}^+$, 100/17). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{22}\text{FNO}_3\text{P}$ ($\text{M} + \text{H}^+$) 314.1316, found 314.1325

Diethyl ((1S*,2S*,5R*)-2-(4-Chlorophenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1c. 0.20 g (0.61 mmol) of **14c** was converted into **1c**. 0.17 g of product was obtained (0.52 mmol, 85% yield, yellow oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.05 (3H, d, $J = 7.2$ Hz), 1.11–1.29 (3H, m, 2H, m), 2.00 (1H, m), 2.53 (1H, br s), 3.15 (2H, br s), 3.72–4.05 (4H, m), 4.49 (1H, d, $^3J_{\text{HP}} = 3.9$ Hz), 7.27–7.31 (2H, m), 7.41–7.44 (2H, m). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.4, 16.1 (d, $^3J_{\text{CP}} = 5.8$ Hz), 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 24.8, 25.7 (d, $^1J_{\text{CP}} = 198.5$ Hz), 47.5, 61.8 (d, $^3J_{\text{CP}} = 5.8$ Hz), 62.0 (d, $^3J_{\text{CP}} = 5.8$ Hz), 62.1 (d, $^2J_{\text{CP}} = 11.5$ Hz), 128.2, 129.4, 133.4, 138.3. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 28.32. IR (cm^{-1}) ν_{max} : 1014 (P–O), 1021 (P–O), 1232 (P=O), 1491, 2924, 3423. MS (ESI, pos): m/z 330.3/331.3/332.3 ($\text{M} + \text{H}^+$, 100/17/32). HRMS: m/z calcd for $\text{C}_{15}\text{H}_{22}\text{ClNO}_3\text{P}$ ($\text{M} + \text{H}^+$) 330.1021, found 330.1024.

Diethyl ((1S*,2S*,5R*)-2-(4-Methoxyphenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1e. 87 mg (0.27 mmol) of **14e** was converted into **1e**. 81 mg of product was obtained (0.25 mmol, 92% yield, yellow oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.03 (3H, t, $J = 7.2$ Hz), 1.19–1.33 (3H, t, $J = 7.2$ Hz, 2H, m), 1.96–2.04 (1H, m), 3.15, 3.71–4.09 (4H, m), 3.80 (3H, s), 4.52 (1H, d, $^3J_{\text{HP}} = 4.4$ Hz), 6.86 (2H, d, $J = 8.3$ Hz), 7.41 (2H, d, $J = 8.3$ Hz). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.6, 16.1 (d, $^3J_{\text{CP}} = 6.9$ Hz), 16.5 (d, $^3J_{\text{CP}} = 6.9$ Hz), 24.3, 25.5 (d, $^1J_{\text{CP}} = 198.5$ Hz), 47.3, 55.3, 61.8 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.1 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.5 (d, $^2J_{\text{CP}} = 11.5$ Hz), 113.6, 129.2, 130.6, 159.4. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 27.95. IR (cm^{-1}) ν_{max} : 1019 (P–O), 1177 (P–O), 1249 (P=O), 1514, 1607, 2918, 3429. MS (ESI, pos): m/z 326.3/327.3 ($\text{M} + \text{H}^+$, 100/18). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{25}\text{NO}_4\text{P}$ ($\text{M} + \text{H}^+$) 326.1516, found 326.1521.

Diethyl ((1S*,2S*,5R*)-2-(4-Methylphenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1f. 75 mg (0.24 mmol) of **14f** was converted into **1f**. 47 mg of product was obtained (0.15 mmol, 63% yield, yellow oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.03 (3H, t, $J = 6.9$ Hz), 1.21–1.30 (3H, t, $J = 7.2$ Hz, 2H, m), 1.91–2.21 (2H, m), 2.33 (3H, s), 3.15 (2H, br s), 3.67–4.05 (4H, m), 4.50 (1H, d, $^3J_{\text{HP}} = 3.9$ Hz), 7.12 (2H, d, $J = 8.0$ Hz), 7.36 (2H, d, $J = 8.0$ Hz). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.5, 16.1 (d, $^3J_{\text{CP}} = 6.9$ Hz), 16.5 (d, $^3J_{\text{CP}} = 6.9$ Hz), 21.2, 24.9, 25.7 (d, $^1J_{\text{CP}} = 197.3$ Hz), 47.7 (d, $^3J_{\text{CP}} = 3.5$ Hz), 61.7 (d, $^2J_{\text{CP}} = 6.9$ Hz), 61.9 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.8 (d, $^2J_{\text{CP}} = 10.4$ Hz), 127.8, 128.9, 136.4, 137.5. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 28.62. IR (cm^{-1}) ν_{max} : 1020 (P–O), 1177 (P–O), 1236 (P=O), 1443, 2978. MS (ESI, pos): m/z 310.3/311.3 ($\text{M} + \text{H}^+$, 100/18). HRMS: m/z calcd for $\text{C}_{16}\text{H}_{25}\text{NO}_3\text{P}$ ($\text{M} + \text{H}^+$) 310.1567, found 310.1569.

Diethyl ((1S*,2S*,5R*)-2-([1,1'-Biphenyl]-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1g. 0.12 g (0.32 mmol) of **14g** was converted into **1g**. 0.11 g of product was obtained (0.30 mmol, 91% yield, pale yellow solid). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.03 (3H, t, $J = 7.2$ Hz), 1.28 (3H, t, $J = 7.2$ Hz, 2H, m), 1.99–2.09 (1H, m), 3.19 (2H, d, $J = 1.7$ Hz), 3.73–4.14 (4H, m), 4.58 (1H, d, $^3J_{\text{HP}} = 4.4$ Hz), 7.21–7.26 (1H, m), 7.32–7.37 (1H, m), 7.42–7.47 (2H, m), 7.56 (2H, s), 7.56–7.60 (3H, m). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.5, 16.1 (d, $^3J_{\text{CP}} = 6.9$ Hz), 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 24.9, 25.9 (d, $^1J_{\text{CP}} = 198.5$ Hz), 47.7 (d, $^3J_{\text{CP}} = 3.5$ Hz), 61.8 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.0 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.7 (d, $^2J_{\text{CP}} = 10.4$ Hz), 126.9, 127.1, 127.4, 128.4, 128.9, 138.9, 140.7, 141.0. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 28.59. IR (cm^{-1}) ν_{max} : 1017 (P–O), 1052 (P–O), 1233 (P=O), 1484, 2982. MS (ESI, pos): m/z 372.3/373.3 ($\text{M} + \text{H}^+$, 100/23). HRMS: m/z calcd for $\text{C}_{21}\text{H}_{27}\text{NO}_3\text{P}$ ($\text{M} + \text{H}^+$) 372.1723, found 372.1718.

Diethyl ((1S*,2S*,5R*)-2-(3-Methoxyphenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1h. 88 mg (0.27 mmol) of **14h** was converted into **1h**. After column chromatography 26 mg of product was obtained (0.08 mmol, 30% yield, yellow oil). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 1.04 (3H, t, $J = 7.3$ Hz), 1.19–1.29 (3H, t, $J = 7.3$ Hz, 2H, m), 1.96–2.02 (1H, m), 2.04 (1H, br s), 3.16 (2H, s), 3.69–4.16 (4H, m), 3.81 (3H, s), 4.51 (d, $^3J_{\text{CP}} = 4.4$ Hz), 6.82 (1H, dd, $J = 7.8$ Hz, $J = 4.5$ Hz), 7.05–7.09 (2H, m), 7.23 (1H, dd, $J = 7.3$ Hz, $J = 7.3$ Hz). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ : 8.6, 16.1 (d, $^3J_{\text{CP}} = 6.9$ Hz), 16.5 (d, $^3J_{\text{CP}} = 5.8$ Hz), 25.0, 25.7 (d, $^1J_{\text{CP}} = 197.3$ Hz), 47.7 (d, $^3J_{\text{CP}} = 3.5$ Hz), 55.3, 61.7 (d, $^2J_{\text{CP}} = 6.9$ Hz), 61.9 (d, $^2J_{\text{CP}} = 5.8$ Hz), 62.9 (d, $^2J_{\text{CP}} = 10.4$ Hz), 113.2, 113.7, 120.2, 129.1, 141.3, 159.5. $^{31}\text{P NMR}$ (121 MHz, CDCl_3) δ : 28.53. IR (cm^{-1}) ν_{max} : 1020 (P–O), 1232 (P=O), 1438,

1602, 2981, 3308. MS (ESI, pos): m/z 326.3/327.3 ($M + H^+$, 100/17). HRMS: m/z calcd for $C_{16}H_{25}NO_4P$ ($M + H$)⁺ 326.1516, found 326.1512. Chromatography: EtOAc, R_f = 0.08.

Diethyl ((1*S,2*S**,5*R**)-2-(4-Nitrophenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1i.** 70 mg (0.21 mmol) of **14i** was converted into **1i**. After column chromatography 58 mg of product was obtained (0.17 mmol, 81% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ: 1.06 (3H, t, J = 7.2 Hz), 1.13–1.21 (2H, m), 1.28 (3H, t, J = 7.2 Hz), 1.85 (1H, br s), 2.03–2.11 (1H, m), 3.22 (2H, br s), 3.74–4.09 (4H, m), 4.63 (1H, d, ³ J_{HP} = 4.4 Hz), 7.69 (2H, d, J = 8.8 Hz), 8.18 (2H, d, J = 8.8 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 8.5, 16.2 (d, ³ J_{CP} = 6.9 Hz), 16.5 (d, ³ J_{CP} = 6.9 Hz), 25.0, 26.1 (d, ¹ J_{CP} = 200.8 Hz), 47.4 (d, ³ J_{CP} = 3.5 Hz), 61.9 (d, ² J_{CP} = 6.9 Hz), 62.0, 62.1 (d, ² J_{CP} = 6.9 Hz), 123.3, 129.0, 147.6, 147.9. ³¹P NMR (121 MHz, CDCl₃) δ: 27.72. IR (cm⁻¹) ν_{max} : 1023 (P–O), 1238 (P=O), 1347 (N–O), 1520 (N–O), 2982, 3303. MS (ESI, pos): m/z 341.3/342.3 ($M + H^+$, 100/17). HRMS: m/z calcd for $C_{15}H_{22}N_2O_5P$ ($M + H$)⁺ 341.1261, found 341.1265. Chromatography: EtOAc, R_f = 0.07.

Diethyl ((1*S,2*S**,5*R**)-2-(4-Pentanoylphenyl)-3-azabicyclo[3.1.0]hexan-1-yl)phosphonate 1j.** 51 mg (0.14 mmol) of **14j** was converted into **1j**. After column chromatography 32 mg of product was obtained (0.08 mmol, 60% yield, yellow oil). ¹H NMR (300 MHz, CDCl₃) δ: 0.95 (3H, t, J = 7.5 Hz), 1.02 (3H, t, J = 7.0 Hz), 1.17–1.29 (3H, t, J = 7.0 Hz, 2H, m), 1.41 (2H, sext, J = 7.5 Hz), 1.71 (2H, quint, J = 7.5 Hz), 1.85 (1H, br s), 1.99–2.09 (1H, m), 2.95 (2H, t, J = 7.5 Hz), 3.19 (2H, s), 3.69–4.07 (4H, m), 4.57 (d, ³ J_{HP} = 4.4 Hz), 7.58 (2H, d, J = 8.0 Hz), 7.91 (2H, d, J = 8.0 Hz). ¹³C NMR (75 MHz, CDCl₃) δ: 8.5, 14.0, 16.1 (d, ³ J_{CP} = 5.8 Hz), 16.5 (d, ³ J_{CP} = 6.9 Hz), 22.6, 24.9, 25.9 (d, ¹ J_{CP} = 199.6 Hz), 26.7, 38.5, 47.6 (d, ³ J_{CP} = 3.5 Hz), 61.8 (d, ² J_{CP} = 5.8 Hz), 62.0 (d, ² J_{CP} = 5.8 Hz), 62.5 (d, ² J_{CP} = 11.5 Hz), 128.0, 128.2, 136.6, 145.2, 200.5. ³¹P NMR (121 MHz, CDCl₃) δ: 28.14. IR (cm⁻¹) ν_{max} : 1025 (P–O), 1238 (P=O), 1681 (C=O), 2931, 3308. MS (ESI, pos): m/z 380.3/381.3 ($M + H^+$, 100/17). HRMS: m/z calcd for $C_{20}H_{31}NO_4P$ ($M + H$)⁺ 380.1985, found 380.1978. Chromatography: EtOAc, R_f = 0.06.

■ ASSOCIATED CONTENT

● Supporting Information

¹H and ¹³C NMR spectra of new compounds as well as ¹H-undecoupled ³¹P NMR spectra of **11i**; crystallographic data for **11i** and **11j** (CIF). This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: chris.stevens@ugent.be.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Research Foundation Flanders (FWO) for financial support. K.V.H. thanks the Hercules Foundation (project AUGÉ/11/029 “3D-SPACE: 3D Structural Platform Aiming for Chemical Excellence”) for funding. Professor Kristof Demeestere and Patrick De Wispelaere are gratefully acknowledged for some urgent analyses.

■ REFERENCES

- (1) De Blicq, A.; Catak, S.; Debrouwer, W.; Drabowicz, J.; Hemelsoet, K.; Verstraelen, T.; Waroquier, M.; Van Speybroeck, V.; Stevens, C. V. *Eur. J. Org. Chem.* **2013**, 1058.
- (2) Mortier, P.; Van Waes, F.; Masschelein, K. G. R.; Heugebaert, T. S. A.; Stevens, C. V. *Tetrahedron Lett.* **2011**, 52, 4273.
- (3) Claeys, D. D.; Stevens, C. V.; Roman, B. I.; Van De Caveye, P.; Waroquier, M.; Van Speybroeck, V. *Org. Biomol. Chem.* **2010**, 8, 3644.
- (4) Van Der Jeught, S.; Masschelein, K. G. R.; Stevens, C. V. *Eur. J. Org. Chem.* **2010**, 1333.

- (5) Dockery, K. P.; Bentrude, W. G. *J. Am. Chem. Soc.* **1994**, 116, 10332.
- (6) Afarinia, K.; Mahmood, F. *Tetrahedron Lett.* **2000**, 41, 1287.
- (7) Griffiths, D. V.; Harris, E. J.; Karim, K.; Whitehead, B. J. *ARKIVOC* **2000**, iii, 304.
- (8) Davies, H. M. L.; Houser, J. H.; Thornley, C. J. *Org. Chem.* **1995**, 60, 7529.
- (9) Brent, D. A.; Copp, R. R.; Farnham, J. G.; Hanson, F. A.; Hendrickson, M. L.; Ockuly, J. C.; Twose, T. M.; Verdome, M. L. *PCT Int. Appl.* 2011, WO 2011/085406 A1.
- (10) Achini, R.; Oppolzer, W.; Gähwiler, B. *Ger. Offen.* 1976, DE 2653251 A1 19770608.
- (11) Alvaro, G.; Cardullo, F.; Castiglioni, E. *PCT Int. Appl.* 2010, WO 2010007032 A1 20100121.
- (12) Brighty, K. E. *US Patent* 1992, US 5164402 A 19921117.
- (13) Castiglioni, E.; Di Fabio, R.; Gianotti, M.; Mesic, M.; Pavone, F.; Rast, S.; Stasi, L. P. *PCT Int. Appl.* 2009, WO 2009/016084 A1.
- (14) Harada, H.; Hatori, K. *PCT Int. Appl.* 2010, WO 2010/064707 A1.
- (15) Corbel, B.; Medinger, L.; Haelters, J.-P.; Sturtz, G. *Synthesis* **1985**, 1048.
- (16) Corbel, B.; L'Hostis-Kervella, I.; Haelters, J.-P. *Synth. Commun.* **2000**, 30, 609.
- (17) Whitesell, M. A.; Kyba, E. P. *Tetrahedron Lett.* **1983**, 24, 1679.
- (18) Panarina, A. E.; Dogadina, A. V.; Ionin, B. I. *Russ. J. Gen. Chem.* **2001**, 71, 147.
- (19) Panarina, A. E.; Dogadina, A. V.; Zakharov, V. I.; Ionin, B. I. *Tetrahedron Lett.* **2001**, 42, 4365.
- (20) Palacios, F.; Ochoa de Retana, A. M.; Pascual, J.; Oyarzabal, J. *J. Org. Chem.* **2004**, 69, 8767.
- (21) Palacios, F.; Garcia, J.; Ochoa de Retana, A. M.; Oyarzabal, J. *Heterocycles* **1995**, 41, 1915.
- (22) Palacios, F.; Ochoa de Retana, A. M.; Oyarzabal, J. *Tetrahedron Lett.* **1996**, 37, 4577.
- (23) Palacios, F.; Ochoa de Retana, A. M.; Oyarzabal, J.; Pascual, J.; Fernandez de Troconiz, G. *J. Org. Chem.* **2008**, 73, 4568.
- (24) Palacios, F.; Aparicio, D.; de los Santos, J. M.; Rodriguez, E. *Eur. J. Org. Chem.* **1998**, 1413.
- (25) Palacios, F.; Aparicio, D.; Garcia, K. *Tetrahedron* **1996**, 52, 906.
- (26) Van der Jeught, S.; De Vos, N.; Masschelein, K. G. R.; Ghiviriga, I.; Stevens, C. V. *Eur. J. Org. Chem.* **2010**, 5444.
- (27) Clark, A. J. *Chem. Soc. Rev.* **2002**, 31, 1.
- (28) Piotrowska, D. G.; Balzarini, J.; Glowacka, I. E. *Eur. J. Med. Chem.* **2012**, 47, 501.
- (29) Masschelein, K. G. R.; Stevens, C. V. *Tetrahedron Lett.* **2008**, 49, 4336.